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Abstract
Background: Fungal peritonitis is a serious complication of peritoneal dialysis (PD) therapy with the majority of patients
ceasing PD permanently. The aims of this study were to identify risk factors and clinical associations that may discriminate
between fungal from bacterial peritonitis.
Methods: We retrospectively identified episodes of fungal peritonitis from 2001–2010 in PD patients at Liverpool and
Westmead Hospitals (Australia). Fungal peritonitis cases were matched in a 1:2 ratio with patients with bacterial peritonitis
from each institution’s dialysis registry, occurring closest in time to the fungal episode. Patient demographic, clinical and
outcome data were obtained from the medical records.
Results: Thirty-nine episodes of fungal peritonitis (rate of 0.02 episodes per patient-year of dialysis) were matched with 78
episodes of bacterial peritonitis. Candida species were the commonest pathogens (35/39; 90% episodes) with Candida
albicans (37%), Candida parapsilosis (32%) and Candida glabrata (13%) the most frequently isolated species. Compared to
bacterial peritonitis, fungal peritonitis patients had received PD for significantly longer (1133 vs. 775 catheter-days;
p=0.016), were more likely to have had previous episodes of bacterial peritonitis (51% vs. 10%; p=0.01), and to have
received prior antibacterial therapy (51% vs. 10%; p=0.01). Patients with fungal peritonitis were less likely to have fever and
abdominal pain on presentation, but had higher rates of PD catheter removal (79% vs. 22%; p,0.005), and permanent
transfer to haemodialysis (87% vs. 24%; p,0.005). Hospital length of stay was significantly longer in patients with fungal
peritonitis (26.1 days vs. 12.6 days; p=0.017), but the all-cause 30-day mortality rate was similar in both groups. Fluconazole
was a suitable empiric antifungal agent; with no Candida resistance detected.
Conclusion: Prompt recognition of clinical risk factors, initiation of antifungal therapy and removal of PD catheters are key
considerations in optimising outcomes.
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Introduction
Patients with end stage kidney disease (ESKD) undergoing
dialysis are at increased risk of infections, with infection-related
hospitalisation rates 31–68% higher than patients without kidney
disease [1]. The route of dialysis determines the principal dialysis-
associated infection type; peritonitis occurs almost exclusively in
peritoneal dialysis (PD) patients. PD peritonitis is common (annual
rates of ,0.6 episodes per patient-year in the United States and
Australia) [1,2] and accounts for up to 16% of all deaths in PD
patients [3]. Most peritonitis episodes are due to bacteria, with
fungi causing only 2–10% of cases [4–6]. Although uncommon
compared with bacterial peritonitis, fungal peritonitis is associated
with higher mortality rates (5%–53% vs. 0.7%–15%) [4,7] and
often results in permanent discontinuation of PD with high
morbidity [4,8].
Management of PD peritonitis requires initiation of empiric
antimicrobial therapy directed against Gram-positive and
Gram-negative, organisms [3], whilst awaiting definitive iden-
tification and susceptibility data of the aetiologic pathogen. For
fungal peritonitis, the guidelines also emphasise the importance
of prompt catheter removal to reduce the high attendant
morbidity and mortality [3]. Since laboratory results are often
non-specific and mycological information may be delayed, it is
important to recognise risk factors, clinical features and
laboratory variables that discriminate fungal, from bacterial,
peritonitis to guide early initiation of targeted antifungal
therapy.
Herein, we examine clinical and epidemiological data from a
multicentre case control study of PD patients to identify unique
risk factors and clinical associations of fungal, compared to
bacterial, peritonitis episodes.
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28247Results
A total of 1568 PD peritonitis episodes occurred in 2075
patients over the 9-year study period (rate of 1 episode every 15
patient-month or ,0.8 episodes every patient-year). Thirty-nine
(2.5%) episodes (in 39 patients) were due to fungi (rate of 0.02
episodes every patient-year). The median age of patients with
fungal peritonitis was 64 years (range 51–77); 51% were female.
Most episodes occurred in patients with their first PD catheter
following mean PD duration of 1133 catheter-days (interquartile
range 466–1710). All patients were receiving CAPD.
Causative fungal pathogen
Candida species accounted for 35 of 39 (90%) fungal peritonitis
episodes (Table 1). The remaining four episodes were caused by
Trichosporon beigelii, Rhodotorula mucilaginosa, Curvularia lunata and
Prototheca wickerhamii (one episode each). Thirty-three of fungal
peritonitis episodes were monomicrobial, and six, polymicrobial
(three episodes were caused by two different Candida species and in
three other episodes, infection was caused by both a Candida and
bacterium).
Thirty-eight Candida isolates were recovered. Fourteen of 38
(37%) of Candida isolates were Candida albicans; 12 (32%) were
Candida parapsilosis; five (13%), Candida glabrata; and three (8%),
Candida tropicalis. There was a single episode each due to Candida
famata and Candida guilliermondii. Two Candida isolates were not
speciated (Table 1). Blood cultures performed in 27 fungal
episodes isolated C. glabrata once in a patient with C. glabrata
peritonitis. Two patients had concurrent/prior exit site infections
with the same fungus recovered in the preceding five and 12 days,
respectively, of their peritonitis episodes.
In vitro antifungal susceptibility testing performed on 36
speciated Candida isolates using Sensititre YeastOne (TREK
Diagnostic Systems, Inc., Cleveland, OH) and/or Etest (AB
BIODISK, Solna, Sweeden), demonstrated fluconazole MICs of
#4 mg/ml (n=32), 8 mg/ml (n=2) and 16 mg/ml (n=2) [9].
Amphotericin MICs available for 36 isolates were 0.032 mg/ml
(n=1); 0.12 mg/ml (n=4); 0.125 mg/ml (n=3); 0.25 mg/ml
(n=8); 0.38 mg/ml (n=1); 0.5 mg/ml (n=13); and 1 mg/ml
(n=6). Caspofungin MICs available for 24 isolates were
0.03 mg/ml (n=3); 0.06 mg/ml (n=8); 0.12 mg/ml (n=3);
0.25 mg/ml (n=4); and 0.5 mg/ml (n=6).
Comparison of fungal and bacterial peritonitis
Patient demographics, major co-morbidities, risk factors, clinical
features and laboratory parameters associated with fungal, and
bacterial, peritonitis episodes are summarised in Table 2.
Underlying co-morbidities and causes of ESKD were similar in
both patient groups; the single patient with ESKD due to systemic
lupus erythematosus had fungal peritonitis (Table 2). Episodes of
fungal peritonitis were associated with significantly longer duration
of PD (1133 vs. 775 catheter-days, p=0.016), greater likelihood of
previous bacterial peritonitis (51% vs. 10%, p=0.01) and receipt
of prior antibacterial agents (51% vs. 10%, p=0.01). Conversely,
patients with bacterial peritonitis were more likely to have been
anaemic and suffer hyperparathyroidism, as reflected by more
frequent use of erythropoiesis-stimulating (p,0.005), and calcimi-
metic agents (p=0.02) respectively (Table 2).
Fever and abdominal pain were more common in bacterial
compared to fungal peritonitis (54% vs. 26%, p,0.05 and 99% vs.
85%, p,0.05 respectively), while there was a trend towards fungal
peritonitis if hypotension was present. Gram stain of peritoneal
fluid showed the presence of yeast in 8/25 (32%) episodes; in 15
cases, no organisms were seen and in two, only bacteria were
visualised although cultures subsequently yielded both Candida and
bacterial infection. Other laboratory parameters in fungal and
bacterial peritonitis were in general, similar although the median
peripheral blood white cell count was higher in fungal peritonitis
(p=0.05) (Table 2).
Treatment and outcomes
Fluconazole was the main antifungal agent prescribed in fungal
peritonitis (33 or 82% of cases); six patients received intravenous
fluconazole monotherapy for the duration of the treatment course
whilst 27 received intravenous, followed by oral therapy.
Liposomal amphotericin B monotherapy was given in 11% of
episodes (one each of R. mucilaginosa, P. wickerhamii, C. glabrata and
C. parapsilosis peritonitis). Voriconazole (oral) and caspofungin
(intravenous) at recommended doses were given in one instance
each of C. lunata and C. tropicalis/C. glabrata infection, respectively.
Flucytosine was not prescribed. Patients with fungal peritonitis
received antifungal therapy for a mean duration of 24 days (vs. 11
days of antibacterial therapy in bacterial peritonitis episodes;
p=0.017). The majority of fungal peritonitis patients were treated
in hospital and had a mean length of stay of 26.1 days compared
with 12.6 days for bacterial infections (p=0.017). Fungal episodes
were also associated with higher rates of PD catheter removal
(79% vs. 22%, p,0.005) and permanent cessation of PD (87% vs.
24%, p,0.005); reasons for catheter retainment were death (n=3
patients), refusal of removal (n=2) and decision for palliative
treatment (n=3).
The all-cause 30-day mortality was similar in both peritonitis
groups (15% vs. 14%, p=0.853), as was the need for infection-
related surgery (these included adhesiolysis, colectomy post
perforation and resection with primary anastomosis) during
catheter removal (18% vs. 15%, p=0.79; Table 2). By univariate
analysis, factors associated with increased mortality in patients
with fungal peritonitis were age .65 years (p=0.009), previous
bacterial peritonitis (p=0.02) and polymicrobial infection
(p=0.011) (Table 3). Conversely, PD catheter removal was
Table 1. Fungal isolates in thirty nine episodes of fungal
peritonitis.
Fungal species
aNo. of isolates (%)
bCandida species (n=38)
Candida albicans 14 (37%)
Candida parapsilosis 12 (32%)
Candida glabrata 5 (13%)
Candida tropicalis 3 (8%)
Candida famata 1 (2.5%)
Candida guilliermondii 1 (2.5%)






aForty-two isolates were responsible for 39 episodes of fungal peritonitis;
percentages are relative to total Candida isolates (n=38).
bThirty-eight Candida isolates (29 monomicrobial episodes with 29 Candida
isolates and 6 polymicrobial episodes with 9 Candida isolates [3 dual Candida
infections and 3 mixed Candida/bacterial infections]).
doi:10.1371/journal.pone.0028247.t001
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occurred in patients with persistent sepsis from retained catheters.
Discussion
Fungal peritonitis in PD patients remains an important clinical
entity with significant morbidity and implications for the
continuation of PD. In contrast to bacterial peritonitis, the
majority of patients with fungal peritonitis cease PD permanently
and commence haemodialysis. Heightened awareness and early
recognition of fungal peritonitis is central to optimise patient care
as well as preserving the existing renal replacement therapy
option. In the present study, we have identified (relative to
bacterial infection) a number of clinical variables that may assist
clinicians in differentiating fungal from bacterial infection.
The proportion of peritonitis episodes caused by fungi in our
study (2.5%) is lower than that reported in a previous Australian
study (4.5%) [4]; however, this proportion may vary across
different regions in Australia (0–15%), with the highest rates
reported in indigenous populations in Western Australia (WA) and
the Northern Territory (NT) [4]. The proportion of fungal
Table 2. Comparison of patients with fungal versus bacterial peritonitis.
Characteristics
Fungal Peritonitis
n=39 (%) Bacterial Peritonitis (n=78 (%) P value
Median age (years 6 SD) 64613 61613 0.20
Female 20 (51) 36 (46) 0.74
Diabetes mellitus 18 (46) 41 (53) 0.64
Ischaemic heart disease 16 (38) 35 (46) 0.84
Solid organ tumour 5 (8) 4 (4) 0.76
Aetiology ESKD
Diabetes mellitus 18(46) 41(53) 0.64
Chronic Glomerulonephritis 7(18) 14(18) 0.79
Hypertension 5(13) 12(15) 0.80
Polycystic kidney disease 3 (8) 2(3) 0.33
Systemic lupus erythematosus 1 0 -
Other
a 6(15) 9(12) 0.77
Markers of ESKD severity
Anaemia 16 (41) 64 (82) ,0.005
Hyperparathyroidism 6 (15) 29 (37) 0.02
Duration of dialysis (catheter days) 1133 775 0.016
Prior bacterial peritonitis episodes 20 (51) 8 (10) 0.01
Receipt of antibacterial therapy within the preceding 30 days 20 (51) 8 (10) 0.01
Clinical/Laboratory findings
Abdominal pain 33 (85) 77 (99) 0.04
Fever 10 (26) 42 (54) ,0.01
Hypotension 12 (31) 11 (14) 0.06
Median blood WCC (cells610
9/L) 12 10 0.05
Median effluent WCC (cells610
6/L) 2094 7973 0.16
Median CRP (mg/L) 190 179 0.73
Outcomes at 30 days
Technique failure 34 (87) 19 (24) ,0.005
Infection related surgery 7 (18) 12 (15) 0.79
All-cause mortality 6 (15) 11 (14) 0.85
aIncludes cancer chemotherapy-induced, analgesic nephropathy, chronic pyelonephritis, renal calculi disease. ESKD=end stage kidney disease.
doi:10.1371/journal.pone.0028247.t002






n=33 (%) P value
Univariate analysis
Sex (Female) 3 (50) 17 (52) 0.09
Mean age (years 6 SD) 77656 2 613 0.01
Diabetes mellitus 3 (50) 15 (45) 0.83
Anaemia 4 (67) 22 (67) 0.34
Hyperparathyroidism 1 (17) 5 (15) 0.92
Previous peritonitis 6 (100) 14 (42) 0.02
Peritoneal dialysis catheter removed 2 (33) 29 (88) 0.01
Polymicrobial infection 3 (50) 3 (9) 0.01
doi:10.1371/journal.pone.0028247.t003
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population of metropolitan New South Wales was similar to the
rate reported in Australian states other than WA and NT (0–3.5%)
[4]. Overall, the rate of fungal peritonitis (0.02 episodes per
patient-year) was also lower than that previously observed (0.03
episodes per patient-year) [4].
A key finding of the present study was that a relatively
prolonged duration of PD was significantly associated with
increased risk for developing fungal peritonitis, an observation
not previously reported. Fungal contamination of peritoneal fluid
may result from inadequate sterile technique when connecting PD
catheters to dialysate bags, exit site and catheter tunnel infections,
intestinal perforation or fistulae track formation [10]. However,
the relative protracted timeframe in which fungal peritonitis
occurred in our study argues against inadequate sterile technique,
particularly in the immediate period following commencement of
PD. We postulate that this association may be in fact due to the
late recognition of fungal peritonitis or because of the high rates of
PD catheter retention following previous bacterial peritonitis
episodes.
Diabetes mellitus was not a risk factor for fungal peritonitis in the
present study, as have been previously noted [11,12]. Consistent
with the findings of others, prior bacterial peritonitis and receipt of
antibacterial therapy in the preceding 30 days were associated with
the development of fungal peritonitis [8,13]. Fungal peritonitis may
have been initially misdiagnosed as bacterial peritonitis prior to
laboratory confirmation of the former, prompting the prescription
of empirical antibacterial therapy. On the other hand, the change in
intestinal flora as a result of antibacterial therapy promotes the
proliferation and transmural migration of fungi across the intestinal
mucosa, increasing the risk of fungal peritonitis in the peritoneal
cavity [6,8,14]. Previous reports have noted that secondary fungal
peritonitis can be prevented by prophylactic antifungal use
(fluconazole or nystatin) in patients receiving antibacterial therapy
[15,16],butthisisnotastrategythatiswidelyadoptedinPDcentres
within Australia [4], including ours. The benefits of antifungal
prophylaxis have not been clearly defined [3] and could lead to
emergence of more antifungal-resistant species as previously noted
in other populations [3,17]. In contrast to bacterial peritonitis,
anaemia and hyperparathyroidism were not significantly associated
with fungal peritonitis (Table 1) consistent with previous studies
[18,19]. However, we were unable to examine the potential effects
ofvaryingdosingregimensoferythropoeitin-stimulating agents with
either bacterial or fungal peritonitis; this remains to be studied in
future surveys.
Although observational studies have suggested that the clinical
signs in fungal peritonitis are similar to those of bacterial infection
[8], few studies have systematically compared the clinical
presentation in these two entities. We observed that whilst
abdominal pain is almost universal in bacterial peritonitis, the
relative absence of abdominal pain and fever despite a cloudy
effluent raises the greater likelihood of fungal peritonitis. Previous
reports have documented fever and abdominal pain in 36% and
68% of patients with fungal peritonitis respectively [6] (cf. with
26% and 85% in the present study, Table 2). Sensitivity of gram
stain is low in fungal peritonitis [3] due to the relatively large
volume of fluid examined and presumably low fungal load; we
visualised yeasts in only a third of instances in our study. Yet Gram
stain of peritoneal fluid is recommended by the International
Society for Peritoneal Dialysis in the management of PD
peritonitis since the visualisation of yeasts allows prompt initiation
of antifungal therapy [3].
In the present study, Candida species were the commonest cause
of fungal peritonitis, with C. albicans, C. parapsilosis and C. glabrata
the most often isolated (37%, 32% and 13% of Candida isolates
respectively). Our data is similar to that of other studies where
non-albicans Candida species were more common than C. albicans
[4,6,8]. Guidelines recommend systemic amphotericin and
flucytosine as empiric antifungal therapy whilst awaiting identifi-
cation and susceptibility of the aetiologic fungus [3]. Given that no
Candida isolates were resistant to fluconazole in our study, this
azole agent is an appropriate alternate empiric antifungal agent,
pending species identification and susceptibility. In one large
series, fluconazole monotherapy was used in 90% of fungal
peritonitis cases; however, the impact of this strategy is uncertain
as microbiological data on causative species and susceptibility were
not presented [4]. An echinocandin (e.g. caspofungin) may be
required to treat azole-resistant yeasts such as C. krusei or C. glabrata
peritonitis [9]. Hence, where possible, all Candida isolates should be
identified to species level, and antifungal susceptibility testing done
to guide therapy. Although non-yeast fungi are occasionally
reported to cause fungal peritonitis, Candida species still account for
the majority of cases [4,6,8]. The newer azoles, voriconazole and
posaconazole may be alternatives to amphotericin B when
filamentous fungi are cultured [3]. Systematic study of larger
numbers of patients are required to determine their position in the
treatment of fungal peritonitis.
The overall mortality rate of fungal peritonitis has been
reported to be 9–60%; with increased age, abdominal pain (with
or without fever) and retained PD catheters the most frequently
identified factors predicting mortality [4,5,8,20]. In the present
study, increased mortality was noted in those with retained
catheters, emphasising the importance of prompt catheter removal
when managing fungal peritonitis [3]. Although late (especially
after 5 days following diagnosis) catheter removal has been
associated with poorer survival [6,21], this was not found in this
and several other studies, perhaps due to the high rates of catheter
removal at the outset and prompt initiation of antifungal therapy
[4,22]. This may have also accounted for the equivalent mortality
rates between fungal and bacterial peritonitis that was observed, in
contrast to previous reports of higher mortality rates for fungal
peritonitis [3,6]. Notably, fungal peritonitis patients with polymi-
crobial infection were more likely to die (Table 3). Fungal
peritonitis was significantly associated with longer hospital stay,
removal of the PD catheter, commencement of haemodialysis and
receipt of systemic antifungal therapy.
The limitations of our study include the retrospective nature of
the study, the lack of PD submodality analysis (continuous
ambulatory vs. automated) as other potential risk factors for
fungal peritonitis, and the potential biases that may have been
introduced when matching fungal to bacterial peritonitis using PD
registries, and by survivor bias. Our small sample size, although
not enabling multivariate analysis for risk of death and involving
only two large referral institutions, is nevertheless representative of
the population of patients that suffer PD-related infectious
complications.
In conclusion, fungal peritonitis is a serious PD-related
complication. Morbidity is high and permanent cessation of
peritoneal dialysis common despite adherence to management
guidelines. Prompt recognition, especially in patients who have
had their catheter in situ for a prolonged period, and removal of
the catheter are key considerations in optimising outcomes.
Methods
Ethics Statement
Approval was obtained from the respective Human Research
Ethics Committees of the Sydney West (SCA2008/8/5.3 [2846])
Differentiating Fungal from Bacterial Peritonits
PLoS ONE | www.plosone.org 4 December 2011 | Volume 6 | Issue 12 | e28247and Sydney South West (QA2009/071) Area Health Services. As
the study was performed retrospectively with no intervention arm,
the need for patient consent was waived by the Ethics Committees.
Episodes of fungal peritonitis occurring between January 2001
to March 2010 in PD patients at Liverpool and Westmead
Hospitals (Sydney, New South Wales, Australia) were retrospec-
tively identified from both institution’s microbiology laboratory
information systems and medical records. An episode of peritonitis
was defined as the presence of any clinical sign of peritonism
(including fever, abdominal tenderness and rebound tenderness) or
peritoneal fluid (effluent) leucocyte count of .100610
6/L with a
positive microbiological culture [4].
Fungal peritonitis cases were matched in a 1:2 ratio with
patients diagnosed with bacterial peritonitis from each institution’s
dialysis registry, occurring closest in time to the fungal episode.
Denominator data obtained included the total patient-years of
dialysis for the entire period.
Each patient’s medical record was examined for demographic
data and relevant history pertaining to ESKD (including aetiology,
severity [as determined by erythropoietin-stimulating agent and
phosphate binder/calcimimetic use], the date of PD commence-
ment and duration of PD with the current catheter [inferred from
the date of catheter insertion]). Data on previous peritonitis
episodes, antibiotic use within the preceding 30 days, clinical
symptoms and signs (e.g. fever, abdominal pain, hypotension) on
presentation were also extracted, as was the presence of PD
catheter exit site infection, antimicrobial therapy given, surgical
procedures and hospital length of stay (if hospitalised). Laboratory
data obtained include the cellular (white cells) profile results,
identification and antimicrobial susceptibility profile of all positive
peritoneal fluid and blood culture isolates, haematological and
biochemical parameters, and C-reactive protein. Clinical out-
comes including overall (all cause) 30-day mortality and technique
failure (defined as permanent cessation of PD) were recorded.
Data were analysed using SSPS statistical software (version 18.0,
IBM, Chicago, IL). For univariate analyses, categorical variables
were analysed using Fisher’s exact test or x
2 test and for
continuous variables, the student’s t-test; p values,0.05 were
considered statistically significant. Multivariate analysis was not
performed due to the small sample size of fungal peritonitis cases
(n=39).
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